Cleveland Clinic Inks Separate Research Pacts with FTA Therapeutics, Aspect Medical Systems | GenomeWeb

The Cleveland Clinic recently entered into separate research partnerships with a pair of biomedical corporations designed to tap into the clinic's biomedical engineering expertise and medical records database with the goal of commercializing various products and services.

Under the first collaboration, Cleveland Clinic has taken an undisclosed equity stake in clinical-stage pharmaceutical company FTA Therapeutics and plans to co-develop a variety of antimicrobial products, in an alliance that will also benefit FTA's development partner Pure Bioscience.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.